Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.

TitleDiffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.
Publication TypeJournal Article
Year of Publication2011
AuthorsBerrak S, Chawla S, Kim S, Quon H, Sherman E, Loevner LA, Poptani H
JournalAcad Radiol
Volume18
Issue10
Pagination1225-32
Date Published2011 Oct
ISSN1878-4046
KeywordsAged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Contrast Media, Diffusion Magnetic Resonance Imaging, Disease Progression, Female, Gadolinium DTPA, Head and Neck Neoplasms, Humans, Image Interpretation, Computer-Assisted, Lymphatic Metastasis, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Statistics, Nonparametric, Survival Analysis, Treatment Outcome
Abstract

RATIONALE AND OBJECTIVES: The aim of this study was to assess the role of diffusion-weighted imaging in predicting progression-free survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with induction chemotherapy.

MATERIALS AND METHODS: Eighteen patients with HNSCC underwent diffusion-weighted imaging studies prior to treatment and within 3 weeks after completion of induction chemotherapy. Median apparent diffusion coefficient (ADC) values were computed from the largest cervical metastatic lymph node. Percentage changes in ADC values from pretreatment to posttreatment time points were compared between alive and dead patients using the Mann-Whitney U test. P values < .05 were considered statistically significant.

RESULTS: A 22% increase in ADC was observed after induction chemotherapy in alive patients (n = 15), while patients who died from HNSCC (n = 3) demonstrated a 33% decrease in ADC. The difference in percentage change in ADC between alive and dead patients was significant (P = .039).

CONCLUSIONS: ADC may be a useful marker in predicting progression-free survival in patients with HNSCC undergoing induction chemotherapy.

DOI10.1016/j.acra.2011.06.009
Alternate JournalAcad Radiol
PubMed ID21835649
PubMed Central IDPMC3168957
Grant ListR01 CA102756 / CA / NCI NIH HHS / United States
R01 CA102756-04 / CA / NCI NIH HHS / United States
R01-CA102756 / CA / NCI NIH HHS / United States
Related Institute: 
MRI Research Institute (MRIRI)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065